Press Releases

Date	Title
Jun 12, 2026	Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Jun 03, 2026	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
May 19, 2026	Alnylam Issues 2025 Corporate Responsibility Report
May 12, 2026	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
May 07, 2026	Alnylam to Webcast Presentations at Upcoming Investor Conferences
May 04, 2026	Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Apr 30, 2026	Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Apr 16, 2026	Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
Mar 30, 2026	New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Mar 24, 2026	Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

MEDIA KIT